A female patient is receiving chemotherapy to cure non-small cell lung cancer. She presents to the infusion clinic and is scheduled to receive both agents today. In the past, the patient has received chemotherapy regimens containing erlotinib, etoposide, docetaxel and gemcitabine.

Chemotherapy regimen:
Cisplatin 100 mg/m2 IV Q4weeks
Vinorelbine 25 mg/m2 IV weekly

Labs:
Hgb (g/dL) = 10.5 (12 - 16)
Hct (%) = 31 (36 - 46)
Plt (cells/mm³) = 202 (150 - 450 x 10³)

Which of the following statements concerning the use of erythropoiesis-stimulating agents (ESAs) in this patient is correct?

A. It is acceptable to use ESAs in this patient based on the chemotherapy treatment goal.
B. It is acceptable to use ESAs in this patient based on the current hemoglobin level.
C. It is not acceptable to use ESAs since the patient does not have chronic kidney disease.
D. It is not acceptable to use ESAs in this patient in combination with the active chemotherapy orders.
E. It is not acceptable to use ESAs in this patient based on the chemotherapy treatment goal.